- Home
- TC vs BCTX Comparison
TC vs BCTX Comparison
Compare TC & BCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TC | BCTX |
|---|---|---|
| Founded | 2010 | 2014 |
| Country | China | Canada |
| Employees | N/A | 4 |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 29.0M | 28.8M |
| IPO Year | 2018 | N/A |
Fundamental Metrics
Financial Performance| Metric | TC | BCTX |
|---|---|---|
| Price | $10.35 | $4.97 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $40.00 |
| AVG Volume (30 Days) | 4.8K | ★ 875.9K |
| Earning Date | 03-26-2026 | 03-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $5,115,721.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $380.95 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $6.50 | $4.10 |
| 52 Week High | $39.00 | $98.20 |
Technical Indicators
Market Signals| Indicator | TC | BCTX |
|---|---|---|
| Relative Strength Index (RSI) | 50.19 | 41.08 |
| Support Level | $8.30 | $4.10 |
| Resistance Level | $11.00 | $4.56 |
| Average True Range (ATR) | 0.76 | 0.62 |
| MACD | 0.49 | -0.10 |
| Stochastic Oscillator | 82.43 | 10.69 |
Price Performance
Historical ComparisonAbout TC TuanChe Limited
Token Cat Ltd is an omnichannel automotive marketplace in China. The company operates in one segment, providing auto shows, special promotion event services, virtual dealerships, online marketing services, and more. It organizes auto shows to facilitate transactions between consumers and auto dealers, which include auto dealers, automakers, and automotive service providers. It offers services through its online platform and offline events.
About BCTX BriaCell Therapeutics Corp.
BriaCell Therapeutics Corp is a clinical-stage biotechnology company focused on developing immunotherapies for cancer treatment, particularly breast cancer. The company's targeted immunotherapy program, Bria-IMT, is a targeted cell-based immunotherapy in end-stage clinical trials aiming to improve outcomes for patients with breast cancer. BriaCell also develops Bria-OTS, personalized off-the-shelf immunotherapies for breast and prostate cancer. BriaCell is involved in clinical collaborations to explore combination therapies for enhanced cancer treatment options.